Updates to Front-line Therapies for Cutaneous Melanoma and How LAG3 Will Impact Treatment

Dr. Luke is the Director of the Immunotherapy and Drug Development Center of UPMC Hillman Cancer Center and Associate Professor of Medicine at the University of Pittsburgh. Dr. Luke is a widely recognized expert in the management of cutaneous malignancies, particularly melanoma. Dr. Luke’s translational research is focused on application of large-scale informatics to advance cancer immunotherapy and he has been a lead investigator for clinical trials of numerous novel immunotherapy agents. Dr. Luke has received research support and/or professional awards from the NIH, DOD, ASCO and multiple professional or private societies. Dr. Luke received his M.D. from the Rosalind Franklin University of Medicine and Science and then trained at Boston University Medical Center and Memorial-Sloan-Kettering Cancer Center. He subsequently has held faculty positions at Dana-Farber Cancer Institute and the University of Chicago.